KR100821105B1 - 유비데카레논 코팅입자 및 아스코르빈산 함유 경구투여용복합제제 - Google Patents
유비데카레논 코팅입자 및 아스코르빈산 함유 경구투여용복합제제 Download PDFInfo
- Publication number
- KR100821105B1 KR100821105B1 KR1020060113501A KR20060113501A KR100821105B1 KR 100821105 B1 KR100821105 B1 KR 100821105B1 KR 1020060113501 A KR1020060113501 A KR 1020060113501A KR 20060113501 A KR20060113501 A KR 20060113501A KR 100821105 B1 KR100821105 B1 KR 100821105B1
- Authority
- KR
- South Korea
- Prior art keywords
- ascorbic acid
- ubide
- ubidecarenone
- carenone
- oral administration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 title claims abstract description 65
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 title claims abstract description 64
- 235000017471 coenzyme Q10 Nutrition 0.000 title claims abstract description 63
- 229960004747 ubidecarenone Drugs 0.000 title claims abstract description 61
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 title claims abstract description 58
- 235000010323 ascorbic acid Nutrition 0.000 title claims abstract description 29
- 229960005070 ascorbic acid Drugs 0.000 title claims abstract description 29
- 239000011668 ascorbic acid Substances 0.000 title claims abstract description 29
- 239000002245 particle Substances 0.000 title claims description 20
- 238000002360 preparation method Methods 0.000 claims abstract description 18
- 238000000576 coating method Methods 0.000 claims description 26
- 239000011248 coating agent Substances 0.000 claims description 25
- 238000000034 method Methods 0.000 claims description 13
- 229920002261 Corn starch Polymers 0.000 claims description 11
- 239000008120 corn starch Substances 0.000 claims description 11
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 11
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 11
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 11
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- 239000008213 purified water Substances 0.000 claims description 8
- 238000002156 mixing Methods 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 239000000725 suspension Substances 0.000 claims description 4
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 3
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 3
- 229930006000 Sucrose Natural products 0.000 claims description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 239000007902 hard capsule Substances 0.000 claims description 2
- 239000007901 soft capsule Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 239000006186 oral dosage form Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 8
- 229940079593 drug Drugs 0.000 abstract description 8
- 238000006243 chemical reaction Methods 0.000 abstract description 7
- 230000000903 blocking effect Effects 0.000 abstract description 2
- 239000000203 mixture Substances 0.000 description 15
- 230000000052 comparative effect Effects 0.000 description 9
- 238000009472 formulation Methods 0.000 description 9
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 238000001179 sorption measurement Methods 0.000 description 6
- 230000003078 antioxidant effect Effects 0.000 description 5
- 239000007921 spray Substances 0.000 description 5
- 238000003860 storage Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 230000008859 change Effects 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000002131 composite material Substances 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 230000000087 stabilizing effect Effects 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 239000002156 adsorbate Substances 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000004217 heart function Effects 0.000 description 2
- 230000002107 myocardial effect Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 description 1
- GWSHTUIRQSLJOC-UHFFFAOYSA-N 4,7,7-trimethylbicyclo[4.1.0]hept-1(6)-en-5-one Chemical compound O=C1C(C)CCC2=C1C2(C)C GWSHTUIRQSLJOC-UHFFFAOYSA-N 0.000 description 1
- 230000002407 ATP formation Effects 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 229920002148 Gellan gum Polymers 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 239000007963 capsule composition Substances 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 229940106189 ceramide Drugs 0.000 description 1
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 1
- 238000006388 chemical passivation reaction Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000008199 coating composition Substances 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 229940110767 coenzyme Q10 Drugs 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 238000009477 fluid bed granulation Methods 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000000216 gellan gum Substances 0.000 description 1
- 235000010492 gellan gum Nutrition 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 210000004536 heart mitochondria Anatomy 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 230000005787 mitochondrial ATP synthesis coupled electron transport Effects 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 229940100691 oral capsule Drugs 0.000 description 1
- 229940100688 oral solution Drugs 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 239000008389 polyethoxylated castor oil Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000007420 reactivation Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 239000002195 soluble material Substances 0.000 description 1
- 239000008347 soybean phospholipid Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- QNTNKSLOFHEFPK-UPTCCGCDSA-N ubiquinol-10 Chemical compound COC1=C(O)C(C)=C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)C(O)=C1OC QNTNKSLOFHEFPK-UPTCCGCDSA-N 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
Landscapes
- Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims (4)
- 유비데카레논(Ubidecarenone)을 히드록시프로필메칠셀룰로오스와 혼합하여 정제수에 현탁시키는 단계;상기 유비데카레논 함유 현탁액을 미결정셀룰로오스, 백당 또는 옥수수전분 중에서 선택된 씨드(Seed)에 흡착시키는 단계;히드록시프로필메칠셀룰로오스와 옥수수전분을 정제수에 용해시킨 코팅액을 제조하는 단계;상기 코팅액을 유비데카레논을 함유한 씨드에 입자코팅시키는 단계; 및상기 코팅된 유비데카레논을 아스코르빈산과 혼합시키는 단계를 포함하는 경구투여용 복합제제의 제조방법.
- 삭제
- 제 1 항에 기재된 방법에 의해 제조되는 경구투여용 유비데카레논 및 아스코르빈산복합제제.
- 제 3 항에 있어서, 경구투여용은 정제, 연질캅셀제, 경질캅셀제, 캅셀제 중에서 선택됨을 특징으로 하는 유비데카레논 및 아스코르빈산복합제제.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020060113501A KR100821105B1 (ko) | 2006-11-16 | 2006-11-16 | 유비데카레논 코팅입자 및 아스코르빈산 함유 경구투여용복합제제 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020060113501A KR100821105B1 (ko) | 2006-11-16 | 2006-11-16 | 유비데카레논 코팅입자 및 아스코르빈산 함유 경구투여용복합제제 |
Publications (1)
Publication Number | Publication Date |
---|---|
KR100821105B1 true KR100821105B1 (ko) | 2008-04-08 |
Family
ID=39534439
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020060113501A Active KR100821105B1 (ko) | 2006-11-16 | 2006-11-16 | 유비데카레논 코팅입자 및 아스코르빈산 함유 경구투여용복합제제 |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR100821105B1 (ko) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101398668B1 (ko) | 2012-03-26 | 2014-05-27 | 신일제약주식회사 | 유비데카레논 및 지용성 비타민을 포함한 비타민 복합제용 가용성 및 흐름성을 개선한 과립 조성물 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005336194A (ja) | 2001-10-10 | 2005-12-08 | Kaneka Corp | 還元型補酵素q10の安定化法 |
JP2006008681A (ja) | 2001-10-10 | 2006-01-12 | Kaneka Corp | 還元型補酵素q10の安定化法 |
KR20070063358A (ko) * | 2005-12-14 | 2007-06-19 | 주식회사 대웅 | 안정화된 코엔자임q10, 종합 비타민 및 미네랄 성분을함유하는 복합제제 |
KR20070078272A (ko) * | 2006-01-26 | 2007-07-31 | 주식회사 대웅제약 | 유비데카레논의 고체분산체와 그 제조방법 및 이를포함하는 약제학적 조성물 |
-
2006
- 2006-11-16 KR KR1020060113501A patent/KR100821105B1/ko active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005336194A (ja) | 2001-10-10 | 2005-12-08 | Kaneka Corp | 還元型補酵素q10の安定化法 |
JP2006008681A (ja) | 2001-10-10 | 2006-01-12 | Kaneka Corp | 還元型補酵素q10の安定化法 |
KR20070063358A (ko) * | 2005-12-14 | 2007-06-19 | 주식회사 대웅 | 안정화된 코엔자임q10, 종합 비타민 및 미네랄 성분을함유하는 복합제제 |
KR20070078272A (ko) * | 2006-01-26 | 2007-07-31 | 주식회사 대웅제약 | 유비데카레논의 고체분산체와 그 제조방법 및 이를포함하는 약제학적 조성물 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101398668B1 (ko) | 2012-03-26 | 2014-05-27 | 신일제약주식회사 | 유비데카레논 및 지용성 비타민을 포함한 비타민 복합제용 가용성 및 흐름성을 개선한 과립 조성물 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4334869B2 (ja) | 溶解性または経口吸収性の改善された組成物 | |
JP2024015361A (ja) | 経口投与に好適なgc-c受容体アゴニストポリペプチドの安定な固体製剤 | |
JP5660544B2 (ja) | 安定性が向上したアムロジピン及びロサルタンを含む固形薬剤的組成物 | |
KR100822133B1 (ko) | 비타민 d 또는 이의 유도체의 고체분산체 및비스포스포네이트를 포함하는, 골다공증 예방 또는 치료용복합제제 | |
JP7196239B2 (ja) | Ed-71の固体分散体および油分分散体を含む医薬組成物 | |
WO1998007417A1 (fr) | Compositions pharmaceutiques contenant de la coenzyme q¿10? | |
CN105007898A (zh) | 难溶性药物的过饱和的稳定纳米颗粒 | |
US20120039949A1 (en) | Stable Solid Formulations of GC-C Receptor Agonist Polypeptides Suitable for Oral Administration | |
KR20010012402A (ko) | 안정한 약제학적 경구 투여형 | |
KR20200015830A (ko) | 안드로겐 수용체 길항제의 고체 제약 조성물 | |
EP2630956B1 (en) | Sustained-release pellets containing tacrolimus as an active ingredient | |
EP3220893B1 (en) | Composition based on coq10 | |
CN113924300A (zh) | 用于达到治疗血浆浓度的增加效能的非晶形固体及经溶解调配物 | |
EP3290037A1 (en) | Pharmaceutical composition for oral administration | |
EP2303866B1 (en) | Crystalline forms of rabeprazole sodium | |
JP5465867B2 (ja) | 安定なエグアレンナトリウム固形製剤 | |
KR100821105B1 (ko) | 유비데카레논 코팅입자 및 아스코르빈산 함유 경구투여용복합제제 | |
KR20070045247A (ko) | 드로스피렌온 및 에티닐에스트라디올을 포함하는 약제학적조성물 | |
CN1646128A (zh) | 固体分散体组合物 | |
TWI740994B (zh) | 經光穩定性提升之固體製劑 | |
RU2410109C1 (ru) | Способ получения нанокомпозиции на основе сахаров | |
RU2734245C1 (ru) | Способ повышения антибактериальной активности фурацилина in vitro | |
ES2560899T3 (es) | Composiciones de diacereína | |
KR20040079325A (ko) | 메트포르민 및 글리부라이드의 고형 경구용 제형 및 이의제조 방법 | |
KR101125453B1 (ko) | 엘-트립토판의 가용화 조성물 및 이를 이용한 제제 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 20061116 |
|
PA0201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20071031 Patent event code: PE09021S01D |
|
E701 | Decision to grant or registration of patent right | ||
PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20080401 |
|
GRNT | Written decision to grant | ||
PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20080402 Patent event code: PR07011E01D |
|
PR1002 | Payment of registration fee |
Payment date: 20080402 End annual number: 3 Start annual number: 1 |
|
PG1601 | Publication of registration | ||
PR1001 | Payment of annual fee |
Payment date: 20110114 Start annual number: 4 End annual number: 4 |
|
PR1001 | Payment of annual fee |
Payment date: 20111206 Start annual number: 5 End annual number: 5 |
|
FPAY | Annual fee payment |
Payment date: 20121128 Year of fee payment: 6 |
|
PR1001 | Payment of annual fee |
Payment date: 20121128 Start annual number: 6 End annual number: 6 |
|
FPAY | Annual fee payment |
Payment date: 20131127 Year of fee payment: 7 |
|
PR1001 | Payment of annual fee |
Payment date: 20131127 Start annual number: 7 End annual number: 7 |
|
FPAY | Annual fee payment |
Payment date: 20141208 Year of fee payment: 8 |
|
PR1001 | Payment of annual fee |
Payment date: 20141208 Start annual number: 8 End annual number: 8 |
|
FPAY | Annual fee payment |
Payment date: 20161123 Year of fee payment: 10 |
|
PR1001 | Payment of annual fee |
Payment date: 20161123 Start annual number: 10 End annual number: 10 |
|
FPAY | Annual fee payment |
Payment date: 20180104 Year of fee payment: 11 |
|
PR1001 | Payment of annual fee |
Payment date: 20180104 Start annual number: 11 End annual number: 11 |
|
FPAY | Annual fee payment |
Payment date: 20190103 Year of fee payment: 12 |
|
PR1001 | Payment of annual fee |
Payment date: 20190103 Start annual number: 12 End annual number: 12 |
|
FPAY | Annual fee payment |
Payment date: 20200107 Year of fee payment: 13 |
|
PR1001 | Payment of annual fee |
Payment date: 20200107 Start annual number: 13 End annual number: 13 |
|
PR1001 | Payment of annual fee |
Payment date: 20201218 Start annual number: 14 End annual number: 14 |
|
PR1001 | Payment of annual fee |
Payment date: 20221220 Start annual number: 16 End annual number: 16 |